978 件 ・ 関連度順
概要と使いどころ
End-to-end observational epidemiology analysis — from research question (PECO Population/Exposure/Comparator/Outcome) to publication-ready statistical report. Covers cohort/case-control/cross-sectional design, regression with confounders, propensity scoring, sensitivity analysis. Writes Python code for every step. Use for epidemiology study analysis, NHANES/UK-Biobank-style analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Evaluate LLM outputs using frontier models as judges. Use for pairwise model comparison, quality scoring with custom rubrics, and automated evaluation pipelines. Covers position bias mitigation, statistical significance, and generating preference data for DPO/RLHF.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end neoantigen discovery from somatic variants to ranked vaccine candidates. Integrates HLA typing, MHC binding prediction, pVACtools neoantigen calling, and immunogenicity scoring. Use when identifying tumor neoantigens for personalized vaccine design or checkpoint biomarkers.
日本語の概要は準備中です。原文の説明を表示しています。
Generate the success criteria for a task or question, then review work against them. Given a task, goal, or open-ended question, decompose it into scenarios, evaluation perspectives, and fine-grained weighted YES/NO criteria using the Recursive Expansion Tree (RET) method; if work is supplied, score it criterion-by-criterion and surface what is missing or could be better. Use when asked to self-review or check your own work, judge whether a task is done well or completely, build a definition-of-done or completeness checklist, create an evaluation rubric or grading criteria, score or grade answers to a question, set up an LLM-as-judge rubric, or when the user mentions self-review, completeness check, success criteria, evaluation criteria, scoring rubric, Qworld, or the RET algorithm.
日本語の概要は準備中です。原文の説明を表示しています。
Assess drug-drug interactions — CYP metabolic interactions (substrate/inhibitor/inducer), transporter (P-gp, BCRP, OATP) effects, pharmacodynamic synergy/antagonism, clinical significance scoring, and management recommendations. Use for polypharmacy review, prescribing decision support, and safety analysis when adding or switching drugs.
日本語の概要は準備中です。原文の説明を表示しています。
Drug safety and adverse event analysis — FAERS spontaneous-report mining, FDA black-box warnings, signal detection (PRR, ROR, IC), risk factors by demographic/comorbidity, and label change tracking. Use for post-market safety surveillance, AE signal investigation, drug-AE association strength scoring, and pharmacovigilance reports.
日本語の概要は準備中です。原文の説明を表示しています。
Pharmacogenomics (PGx) research — drug-gene interactions (CPIC, PharmGKB), CPIC dosing guidelines, variant-drug-response associations, ethnic-allele-frequency considerations, and metabolizer-status scoring. Use for PGx-informed dosing recommendations, CYP/HLA pharmacogenomic allele interpretation, and clinically-actionable PGx report generation.
日本語の概要は準備中です。原文の説明を表示しています。
Turns untargeted LC-MS/MS features (m/z, RT, MS/MS) into confidence-stratified metabolite annotations using spectral-library matching (matchms), in-silico tools (SIRIUS/CSI:FingerID, MetFrag) and molecular networking, and assigns a defensible MSI/Schymanski confidence level to each. Use when naming detected features, scoring MS/MS against a reference library, running SIRIUS, or deciding what confidence level an evidence set actually supports. For upstream feature extraction see metabolomics/xcms-preprocessing and metabolomics/msdial-preprocessing; for downstream enrichment that must respect these levels see metabolomics/pathway-mapping; for lipid-specific structural annotation see metabolomics/lipidomics.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end molecular docking pipeline. Target preparation, pocket detection, protein-ligand docking (DiffDock/Vina), scoring, interaction analysis, and pose ranking.
日本語の概要は準備中です。原文の説明を表示しています。
Multi-method binding pocket detection and druggability assessment. Grid-based, fpocket, and P2Rank detection with druggability scoring, visualization, and cross-structure comparison.
日本語の概要は準備中です。原文の説明を表示しています。
Performs retrosynthetic planning using AiZynthFinder (MCTS, template-based), Chemformer (template-free transformer), ASKCOS, and emerging RetroSynFormer with explicit handling of route scoring, building-block availability (eMolecules, Enamine, Mcule), forward prediction validation (Molecular Transformer), and disconnection-aware multi-objective search (MO-MCTS). Use when assessing synthetic feasibility of generated or selected molecules, planning multi-step syntheses, building synthesis-aware design pipelines, or screening libraries for retro-route feasibility.
日本語の概要は準備中です。原文の説明を表示しています。
Performs structure-based virtual screening using AutoDock Vina, SMINA, GNINA (CNN scoring), and DiffDock-L hybrid workflows with explicit choice rules across rigid vs flexible docking, cross-docking vs self-docking, binding-site detection (P2Rank, fpocket), receptor preparation (PDB2PQR, PROPKA), ligand preparation (meeko, OpenBabel), and ultralarge-library screening (ZINC22, Enamine REAL). Use when screening chemical libraries against a protein target to find candidate binders, ranking docking poses, or selecting a docking workflow for a specific scenario.
日本語の概要は準備中です。原文の説明を表示しています。
Review and rank an entire SCF round end-to-end from a CSV export. Supports Open Track, Integration Track, and RFP Track with track-specific scoring dimensions. Reads submission data directly from an Airtable CSV, auto-detects columns, categorizes, runs parallel batch reviews, cross-batch calibration, and final ranking. All output is markdown. Use when you have a CSV export of an SCF Build Award round and need to review, score, and rank every submission.
日本語の概要は準備中です。原文の説明を表示しています。
Rules for the VenTu data layer — scripts/, public/data/, scores, buoys (IH/WMO), Open-Meteo, IPMA, Ecowitt, news, Dawn Patrol. Use whenever touching data scripts, generated JSON, scoring, staleness display, or any data source.
日本語の概要は準備中です。原文の説明を表示しています。
Build AI lead scoring systems. TRIGGERS - Use when user needs help with ai-lead-scorer related tasks.
日本語の概要は準備中です。原文の説明を表示しています。
Create evaluation frameworks for AI outputs with rubrics and scoring. TRIGGERS - Use when user needs help with ai-evaluation-framework related tasks.
日本語の概要は準備中です。原文の説明を表示しています。
Put two or more Japanese job offers on one basis so they can be read side by side, separating fixed overtime allowance and unguaranteed bonus from the stated annual figure, converting each offer to guaranteed annual pay and to an hourly rate that includes deemed overtime hours, and listing non-monetary terms without scoring them. Use when a user holds more than one offer, wants to know what a stated 年収 actually contains, or wants to see where the ranking changes once the components are separated; do not use to recommend which offer to accept, to score or rank offers, to estimate take-home pay as fact, or to reply to an employer.
日本語の概要は準備中です。原文の説明を表示しています。
Nominates and assesses CRISPR off-target sites genome-wide. Enumerates candidate sites by mismatch and bulge tolerance with Cas-OFFinder/CRISPRitz, ranks them with the published CFD score (SpCas9-only, relative ranker) or MIT/CRISTA/energy models, runs variant-aware screening against gnomAD/individual genomes (CRISPRme), and frames the empirical genome-wide discovery assays (GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-seq, Digenome-seq) and high-fidelity nuclease choice (HiFi Cas9, Sniper-Cas9, eSpCas9, SpCas9-HF1). Use when assessing guide RNA specificity, choosing among candidate guides, screening a therapeutic guide against population variation, or planning empirical off-target validation. Distinguishes predicted vs detected vs validated. On-target activity scoring and deaminase (Cas-independent) base/prime-editor off-targets are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.
日本語の概要は準備中です。原文の説明を表示しています。
Rank and prioritize neoantigen/epitope candidates by likely T-cell response using NeoFox feature annotation, PRIME2.0, BigMHC-IM, the Łuksza/Balachandran fitness model (agretopicity + foreignness), and pVACtools tiering. Encodes the field's hard truths that immunogenicity is the least-solved layer (dedicated scores ~AUROC 0.6-0.7, modest PPV), that scores are valid only for RANKING within one patient (never absolute go/no-go or cross-patient), that DAI has anchor-inflation and WT-denominator traps, and that stacking weak correlated scores into one number is a red flag. Use when ordering a candidate list for a vaccine. Binding lives in mhc-binding-prediction; calling in neoantigen-prediction.
日本語の概要は準備中です。原文の説明を表示しています。
Predict peptide-MHC class I binding and natural presentation with MHCflurry, NetMHCpan-4.1, and MixMHCpred to nominate candidate CD8 T-cell epitopes. Covers the binding-affinity (BA) vs eluted-ligand (EL/presentation) distinction, why %Rank beats raw nM for cross-allele work, the MS abundance bias that misranks low-expression neoantigens, allele-coverage inequity, and length bias. Use when scanning a protein or peptide set for class I epitopes, scoring neoantigen candidates, or choosing a binding predictor. For CD4/HLA class II see mhc-class-ii-prediction.
日本語の概要は準備中です。原文の説明を表示しています。
Predict peptide-MHC class II (HLA-DR/DQ/DP) binding and presentation for CD4 T-cell epitopes with NetMHCIIpan-4.3 and MixMHC2pred-2.0. Covers why class II is far less reliable than class I (open binding groove, 9-mer register ambiguity, sparse noisy training data, DR>DP>DQ accuracy asymmetry), the DQ/DP heterodimer alpha/beta pairing trap, and the looser 1%/5% %Rank thresholds. Use when predicting CD4 epitopes for vaccine help, mapping class II neoantigens, or scoring long peptides against DR/DQ/DP. For CD8/class I see mhc-binding-prediction.
日本語の概要は準備中です。原文の説明を表示しています。
Designs pegRNAs and nicking guides for prime editing (PE) -- choosing the nick/strand, tuning the primer-binding site (PBS) and reverse-transcription template (RTT) as a per-locus panel, selecting the PE system (PE2/PE3/PE3b/PE4/PE5/PEmax/PE7), adding MMR-evading and PAM-disrupting silent edits, appending epegRNA 3' motifs (tevopreQ1/mpknot), and ranking with PRIDICT/DeepPrime. Covers twinPE/PASTE for large insertions and the prime-vs-base-editing decision. Use when designing a scarless point mutation, small insertion/deletion, or any of the 12 base conversions without a double-strand break, when efficiency is low and MMR inhibition or pegRNA stabilization is needed, or when routing a large insertion to an integrase method. Generic guide scoring and base editing are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Tests whether two genomic interval sets overlap (colocalize) more than expected by chance using a permutation test against a structured-genome null model. Covers bedtools fisher (analytic 2x2 screen), bedtools shuffle + jaccard permutation, GAT (isochore/GC-conditioned simulation with FDR), regioneR (flexible permutation, randomizeRegions vs circularRandomizeRegions, localZScore), LOLA (universe-relative Fisher against a region database), and GREAT/rGREAT (regulatory-domain binomial + hypergeometric for ontology-from-regions). Stresses the universe/background choice, matched background, blacklist exclusion, and multiple-testing control. Use when asking whether peaks/regions are enriched at enhancers/TFBS/features, scoring region-set colocalization or region-set enrichment, comparing CNV/SV concordance, or turning an overlap count into a defensible p-value.
日本語の概要は準備中です。原文の説明を表示しています。